NL Journal of Medical and Pharmaceutical Sciences
(ISSN: 3108-0502)

---

A Novel Analysis Technique for Affirming Drug Outcomes in Personalized Medicine

Author(s) : Dhruv Rishab Batra, Dr. Anusha Sunder*.
DOI : 10.71168/NMP.02.02.129

---

Abstract

Traditional scoring systems for pharmacogenomic analysis often fail to account for variability amongst genetic markers, erroneously weighting their contributions on the same level. We introduce a novel hierarchical weighted scoring system that integrates ClinPGx Levels of Evidence/LoE (1A to 4) at the variant-gene level (https://www.pharmgkb.org/) and ‘Clinical Pharmacogenetics Implementation Consortium’ (CPIC) gene-drug grades (A-D) at the drug level to derive actionable suitability scores (https://cpicpgx.org/). Variant genotypes are scored +1 (favourable), -1 (unfavourable), or 0 (intermediate), LoE-weighted, and aggregated to score a gene. This continues at the gene level, with multiple genes aggregating to give a drug suitability score based on the CPIC grade of that drug-gene pair. This scoring model is applied to study the inter-individual suitability of vital drugs for various health conditions. This novel technique accommodates variable contributions at each level of analysis, promising higher accuracy and more actionable results for an end user. While for a medical practitioner, such an analysis technique ensures enhanced clinical utility, duly considering the pooled outcome of contributing gene markers for drug suitability. Keywords: Level of Evidence/LoE, CPIC grade, drug suitability, genetic variants, pharmacogenomics.

This article licensed under the Creative Commons Attribution 4.0 International License CC-BY 4.0., which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.